Compare CRBU & FT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRBU | FT |
|---|---|---|
| Founded | 2011 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.6M | 199.8M |
| IPO Year | 2021 | N/A |
| Metric | CRBU | FT |
|---|---|---|
| Price | $1.59 | $8.01 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $10.75 | N/A |
| AVG Volume (30 Days) | ★ 2.4M | 32.5K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.85% |
| EPS Growth | ★ 3.64 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.63 | N/A |
| Revenue Next Year | $10.93 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.38 | $7.73 |
| 52 Week High | $3.53 | $8.35 |
| Indicator | CRBU | FT |
|---|---|---|
| Relative Strength Index (RSI) | 35.14 | 46.72 |
| Support Level | $1.39 | $8.02 |
| Resistance Level | $1.73 | $8.08 |
| Average True Range (ATR) | 0.11 | 0.06 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 0.94 | 24.62 |
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
Franklin Universal Trust is a closed-end management investment company focused on providing high current income while preserving capital. Its secondary objective is to achieve income growth through dividend increases and capital appreciation. The fund invests in two asset classes: high-yield bonds and utility stocks. It applies fundamental research to build a diversified high-yield bond portfolio and targets utility companies with attractive dividend yields and a history of increasing dividends.